NAD+ vs. NMN vs. NR: Which Delivers Better Results for Patients?

Patients who come to your practice asking about NAD+ therapy have often already done their research — and they have questions about the differences between NAD+, NMN (nicotinamide mononucleotide), and NR (nicotinamide riboside). Understanding these distinctions helps you counsel patients effectively and position your practice's offering appropriately.

To understand the differences between these compounds, you need to understand how the body makes NAD+.

NAD+ is synthesized through several pathways:

The Preiss-Handler pathway: Uses nicotinic acid (niacin/vitamin B3) as a precursor.

The de novo pathway: Synthesizes NAD+ from tryptophan.

The salvage pathway: Recycles nicotinamide (NAM) back into NAD+. This is the most important pathway for maintaining NAD+ levels in most tissues.

The NR/NMN pathway: NR (nicotinamide riboside) and NMN (nicotinamide mononucleotide) are intermediates in the salvage pathway. NR is converted to NMN, which is then converted to NAD+.

NR is a form of vitamin B3 that serves as a direct precursor to NAD+. It is available as an oral supplement (Tru Niagen is the most well-known branded form).

Mechanism: NR → NMN → NAD+

Evidence: Several randomized controlled trials have shown that oral NR supplementation increases blood NAD+ levels. A 2018 study in Nature Communications showed that NR at 1,000 mg/day increased whole blood NAD+ by approximately 60% over 8 weeks.

Limitations:

• Oral bioavailability is subject to first-pass metabolism
• Increases blood NAD+ but tissue-level increases are less certain
• The clinical significance of blood NAD+ increases is not fully established
• Relatively expensive for the level of NAD+ elevation achieved

NMN is one step closer to NAD+ in the biosynthesis pathway than NR.

Mechanism: NMN → NAD+

Evidence: NMN research has accelerated significantly. A 2021 randomized controlled trial in Science showed that oral NMN at 250 mg/day increased blood NAD+ levels and improved muscle insulin sensitivity in postmenopausal women with prediabetes.

Limitations:

• Oral bioavailability questions remain — some research suggests NMN may be converted to NR in the gut before absorption
• The optimal dose is not established
• Long-term safety data is limited
• Regulatory status is uncertain — the FDA has questioned whether NMN can be marketed as a dietary supplement

Rather than using precursors, direct NAD+ supplementation bypasses the biosynthesis pathway entirely.

Mechanism: Direct delivery of NAD+ to tissues

Delivery methods:

• Intravenous (IV): Traditional clinical delivery. High peak levels but requires clinical infrastructure.
• Subcutaneous injection: Emerging as the preferred clinical delivery method. More sustained elevation, home administration possible.
• Oral: Poor bioavailability due to rapid degradation in the GI tract. Not recommended for clinical use.
• Intranasal: Experimental; limited data.

For medical practices offering NAD+ as a clinical service, subcutaneous injection has several advantages over oral precursors:

Higher and more reliable NAD+ elevation: Sub-Q delivery bypasses first-pass metabolism and delivers NAD+ directly to systemic circulation.

Faster onset: Patients often report effects within hours of injection, compared to days or weeks with oral precursors.

Differentiation: Oral NR and NMN are available at any supplement store. Sub-Q NAD+ is a clinical service that requires a prescriber and a licensed compounding pharmacy. This creates a meaningful differentiation for your practice.

Revenue: Sub-Q NAD+ generates significantly more revenue per patient than recommending an oral supplement.

Patient experience: The injection protocol creates a touchpoint with your practice that oral supplements do not.

Patients asking about NAD+ deserve honest counseling:

• All three approaches (NR, NMN, sub-Q NAD+) increase NAD+ levels
• Sub-Q NAD+ produces the highest and most reliable elevation
• The clinical significance of NAD+ elevation is still being established
• Sub-Q NAD+ is a clinical service; oral precursors are supplements
• Cost and convenience differ significantly between approaches

We supply 503A compounded NAD+ subcutaneous injections at 500 mg/mL and 1,000 mg/mL. Valid prescription required.

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice.